GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Immunovia AB (OSTO:IMMNOV) » Definitions » Total Equity

Immunovia AB (OSTO:IMMNOV) Total Equity : kr38.60 Mil (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Immunovia AB Total Equity?

Immunovia AB's total equity for the quarter that ended in Sep. 2024 was kr38.60 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Immunovia AB Total Equity Historical Data

The historical data trend for Immunovia AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovia AB Total Equity Chart

Immunovia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 357.61 599.40 433.90 243.80 66.99

Immunovia AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 93.22 66.99 43.70 19.71 38.60

Immunovia AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Immunovia AB's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=98.681-31.69
=66.99

Immunovia AB's Total Equity for the quarter that ended in Sep. 2024 is calculated as

Total Equity=Total Assets(Q: Sep. 2024 )-Total Liabilities(Q: Sep. 2024 )
=63.099-24.504
=38.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunovia AB Total Equity Related Terms

Thank you for viewing the detailed overview of Immunovia AB's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunovia AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Immunovia AB (OSTO:IMMNOV) » Definitions » Total Equity
Comparable Companies
XSAT:SPERM XSAT:GEAN OSTO:PROGEN XSAT:ALPH XSAT:CALMA B NGM:ATANA OSTO:AROC TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN LH DGX WAT
Traded in Other Exchanges
0G8X:UK
Address
Medicon Village, Scheelevagen 8, Lund, SWE, 223 63
Website
https://www.immunovia.com
Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The company is currently developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer.

Immunovia AB Headlines

No Headlines